Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332413 | 0.92 | CTSL (0.36) | CTSKCTSLCYP4F2CYP4A11 | |
| SCHEMBL15268592 | 0.84 | CTSL (0.33) | CTSKCTSL | |
| SCHEMBL1973582 | 0.84 | USP2 (0.39) | CTSKCTSL | |
| SCHEMBL4187262 | 0.84 | CTSL (0.33) | CTSKCTSL | |
| SCHEMBL16427727 | 0.82 | CTSL (0.32) | CTSKCTSL | |
| SCHEMBL16427906 | 0.81 | CTSL (0.32) | CTSKCTSL | |
| SCHEMBL2780424 | 0.80 | CYP4F2 (0.36) | CTSKCTSLMEN1ALDH1A1MAPT | |
| SCHEMBL5551911 | 0.78 | NPSR1 (0.41) | MEN1ALDH1A1MAPTKMT2ACYP4F2 | |
| SCHEMBL16472495 | 0.74 | DPP4 (0.31) | ALDH1A1 | |
| SCHEMBL100849 | 0.74 | NPSR1 (0.45) | MEN1ALDH1A1MAPTKMT2ACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020015343-A1 | NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS | NANJING RUIJIE PHARMATECH CO., LTD. (CN) | 2020-01-23 | — | — | WO | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| EP-2834220-B1 | 4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9409892-B2 | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9050339-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2616447-B1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-02-18 | — | — | EP | disclosed |
| EP-2834220-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| WO-2013134660-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | EGLN3, HIF1AN, EGLN2 | CTSK 4536/4885CTSL 4738/4885MEN1 4722/4885 |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | CTSK 4303/4885CTSL 4154/4885MEN1 1576/4885 |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | CTSK 4303/4885CTSL 4154/4885MEN1 1576/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | CTSK 4303/4885CTSL 4154/4885MEN1 1576/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | CTSK 4303/4885CTSL 4154/4885MEN1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.